Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
about
Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis.The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.The use of machine learning methodologies to analyse antibiotic and biocide susceptibility in Staphylococcus aureus.Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers.A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agentsProposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltrationSetting and revising antibacterial susceptibility breakpoints.Selective pressure of antibiotic pollution on bacteria of importance to public health.Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists.Pharmacodynamic analysis and clinical trial of amoxicillin sprinkle administered once daily for 7 days compared to penicillin V potassium administered four times daily for 10 days in the treatment of tonsillopharyngitis due to Streptococcus pyogenesAntimicrobial resistance in Haemophilus influenzaeEffect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.The Role of Topical Antiseptic Agents Within Antimicrobial Stewardship Strategies for Prevention and Treatment of Surgical Site and Chronic Open Wound Infection.Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Multiple antimicrobial resistance of gram-negative bacteria from natural oligotrophic lakes under distinct anthropogenic influence in a tropical region.A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates.Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatmentComparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strainsCharacterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae.Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.Coevolution of antibiotic production and counter-resistance in soil bacteria.A combination of mathematical and statistical models to distinguish between "susceptible" and "resistant" clusters in the susceptibility disk diffusion method.Population distributions of minimum inhibitory concentration--increasing accuracy and utility.An evaluation of serum gentamicin concentrations and bacterial susceptibility to gentamicin in equine practice.
P2860
Q33968990-7A37C68A-943B-4854-A344-AC4FF646A254Q34575804-9A27D13D-C2F1-4C12-A653-09609E7DBC2AQ34587708-99D9648C-483A-4176-9060-19EB73F8DA44Q34594968-92474B27-1C90-4C5B-A438-A13D04A23419Q34782459-9F349EB3-EBC6-4589-B48D-45005DA32804Q34993851-4BF2C0DE-F3E6-4331-8DC9-9A3951302E06Q35536173-B8F015BF-DFD3-42DA-983B-6224FAC3793CQ35598435-7EFE901E-785B-468C-B591-BBBDF82A13C0Q35913176-50462C9E-2F04-4603-A595-A664A625F29CQ36229074-8CF77312-1858-4B36-984F-97EA8D96E164Q36515459-1116F0B9-4173-45E1-9D47-C3909C21D4DAQ36744881-DEF14986-B3FB-4474-9A77-04F8D1859A0AQ36788831-C6B12E5C-9717-4EAE-9090-07A22EB0FD70Q37115679-3843BCB5-A09B-4F12-9CFA-C5987EA6D72DQ37274643-85BB08DD-7F65-4B6A-BE6B-A05D852F44E9Q37618374-5DECD6C2-B892-4EB8-935A-6702E809056EQ38186636-CBDB022D-76DF-44F3-B2D8-2B4B011986F4Q39363504-805442CC-0D75-48D0-91C8-2BA22C8DA538Q39955761-D41FB118-F611-493C-A65C-D682FE499EAFQ40111993-36158BFF-1BF5-4831-988A-FD71D3E3210FQ41002282-FA03673F-77F1-47D1-B70D-7738E197E6F3Q41870150-E7618302-AC7A-41F6-976F-D10131524F7AQ41991408-234DFA08-FBDB-4AFC-81DC-286A6FBCCEA5Q42014931-A4542C23-FEA2-4152-BE85-3FC488F528DDQ42040822-36AA185C-FA5F-4BD3-A141-E7A90B18C95BQ42127654-5A226D54-3798-4DE7-90A1-CCBBCA71FC0FQ43097126-FC8E3007-7F15-4D00-A137-91D1E04E3A2EQ44280444-F602965C-2123-4699-8853-50177F106D3CQ51906009-F8767229-B8DD-4C68-893E-2BF5B59D759FQ51943317-16E83921-EB45-46F9-A157-9F858DE13A0DQ54249096-1F82BBF2-A703-4CEC-85C2-16757E2E11F9
P2860
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@ast
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@en
type
label
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@ast
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@en
prefLabel
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@ast
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@en
P356
P1476
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
@en
P2093
P356
10.1093/JAC/48.SUPPL_1.17
P407
P478
48 Suppl 1
P577
2001-07-01T00:00:00Z